Ginkgo Bioworks, a.k.a. “the organism company,” has notched many milestones in its 13-year history, Fortune magazine reports. Founded by four Ph.D. students in bioengineering and computer science at MIT with their professor, the synthetic biology business has partnered with Fortune 500 giants to develop custom strains of organisms used to make everything from fragrances to fertilizers. They have collaborated with Roche to hunt for natural antibiotics in soil. They’ve worked with startups to engineer probiotics to treat disease and to break down plastic pollution. They’ve designed lab-grown proteins that make faux meat taste real. Now they share the story of taking their company public via a SPAC.
The company in May announced a business combination with Soaring Eagle Acquisition that values the engineered biology company at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. Read more.
Related Posts
Investors ‘Scared Off’ Backing UK SPAC: Report
Martin Franklin said that he had been forced to withdraw Harvester Holdings, his proposed $750 million fund, because of pressure from American investors to move the listing to New York.
Tishman Speyer, Billionaire Co-Founder Face SPAC Deal Challenge on Latch Inc.
The company began trading at $10.83 on June 4, 2021. The stock closed today at 76 cents.
Analysis: SPACs Splash the Cash to Salvage Deals
In money terms, almost $9.5 billion worth of mergers have been canned this year.
Goldman Sees a Trade in Some Less Risky SPACs Amid Market Washout: Report
The Wall Street firm said investors could cherry-pick some winners in the cooling market as the discounted deals create an attractive yield.